Research progress on ATP-citrate lyase and its inhibitors: a metabolic-epigenetic perspective
Qinglin Liu, Hongbin Sun, Liang Dai · 2026
Read Research progress on ATP-citrate lyase and its inhibitors: a metabolic-epigenetic perspective by Qinglin Liu, Hongbin Sun, Liang Dai (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13670275.txt.
Description
One enzyme sits where energy use meets gene control. ATP-citrate lyase splits citrate to make acetyl-CoA, a building block cells spend on making fat and on tagging DNA-packaging proteins, which switches genes on or off. Qinglin Liu, Hongbin Sun and Liang Dai review this enzyme and the drugs that block it, viewing both through that double role. Abnormal enzyme activity shows up in metabolic diseases, immune-driven inflammation, cancer, and brain degeneration, which makes it an attractive drug target.
The review moves through three layers: how the enzyme is built and works, how it drives disease, and how blockers are designed and improved. Current blockers struggle with weak selectivity, modest benefit in patients, and side effects elsewhere. By tying the metabolic and gene-control stories together, the authors aim to ground precise therapies. They map where sharper, safer blockers might come from.
Catalog record
| CREATOR | Qinglin Liu, Hongbin Sun, Liang Dai |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 61 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |